Drug intelligence / Profile preview

corticorelin ovine triflutate

Development stage
Approved
Lead developer
Ferring Pharmaceuticals
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous
01

Overview

Corticorelin ovine triflutate is a synthetic peptide that mimics the naturally occurring human corticotropin-releasing hormone (CRH). It acts as a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary gland, which in turn stimulates cortisol production from the adrenal cortex. The drug is primarily used as a diagnostic agent to differentiate between pituitary and ectopic sources of ACTH in patients with ACTH-dependent Cushing's syndrome. If administration leads to increased plasma ACTH and cortisol, it suggests a pituitary source; lack of response indicates an ectopic source. Corticorelin has an amino acid sequence identical to that of ovine CRH and is available under the brand name Acthrel[1][3][7].

Brand names
Acthrel
Other names
corticorelin ovinecorticorelin triflutatecorticotropin-releasing factor (sheep hypothalamus)corticotropin-releasing factor (sheep)ovine ACTH releasing factorovine corticotropin-releasing factorovine CRF 41ovine CRHsheep corticotropin-releasing factorsheep corticotropin-releasing factor (1–41)
02

Targets

CRHR1 (Corticotropin-releasing factor receptor 1)CRHR2 (Corticotropin-releasing hormone receptor 2)

Beyond the preview

Go deeper on corticorelin ovine triflutate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on corticorelin ovine triflutate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call